Morphic Holding Inc
NASDAQ:MORF

Watchlist Manager
Morphic Holding Inc Logo
Morphic Holding Inc
NASDAQ:MORF
Watchlist
Price: 56.99 USD Market Closed
Market Cap: 2.9B USD

Relative Value

There is not enough data to reliably calculate the relative value of MORF.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MORF Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
2
Median 3Y
0
Median 5Y
21.6
Industry
8.2
Forward
11 197
vs History
vs Industry
Median 3Y
-15.9
Median 5Y
-15.9
Industry
24.2
Forward
-14
vs History
vs Industry
Median 3Y
-21
Median 5Y
-21
Industry
23
vs History
vs Industry
Median 3Y
-20.7
Median 5Y
-20.7
Industry
25.5
vs History
28
vs Industry
21
Median 3Y
4.6
Median 5Y
4.6
Industry
3.3
vs History
vs Industry
3
Median 3Y
0
Median 5Y
15.5
Industry
8.6
Forward
8 732.8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.5
vs History
vs Industry
Median 3Y
-10.5
Median 5Y
-10.5
Industry
6.1
Forward
-9.5
vs History
vs Industry
Median 3Y
-10.5
Median 5Y
-10.5
Industry
6.6
Forward
-9.7
vs History
vs Industry
Median 3Y
-16.3
Median 5Y
-16.3
Industry
8.8
vs History
vs Industry
Median 3Y
-16.2
Median 5Y
-16.2
Industry
6.8
vs History
9
vs Industry
1
Median 3Y
150
Median 5Y
143.1
Industry
5.7

Multiples Across Competitors

MORF Competitors Multiples
Morphic Holding Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Morphic Holding Inc
NASDAQ:MORF
2.9B USD 0 -15.9 -10.5 -10.5
IL
Can Fite Biopharma Ltd
TASE:CANF
17.7m ILS 6.4 -0.4 0.1 0.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 170 980.7 -162 409.6 -197 217.1 -194 966.6
US
Abbvie Inc
NYSE:ABBV
383.1B USD 6.4 163.1 15.9 22.5
US
Amgen Inc
NASDAQ:AMGN
177.6B USD 4.9 25.3 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
150.6B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.5B USD 9.5 30.3 22.2 23.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 061.7 -526.1 -572.9 -557.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD 5.5 17.1 16.2 18.4
AU
CSL Ltd
ASX:CSL
85.1B AUD 3.7 19 12.8 16
NL
argenx SE
XBRU:ARGX
43.3B EUR 13.9 32.8 56.4 58
P/S Multiple
Revenue Growth P/S to Growth
US
Morphic Holding Inc
NASDAQ:MORF
Average P/S: 3 417 309.8
Not Available
-8%
N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
6.4
140%
0
FR
Pharnext SCA
OTC:PNEXF
34 170 980.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.5
10%
1
US
E
Epizyme Inc
F:EPE
2 061.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
NL
argenx SE
XBRU:ARGX
13.9
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Morphic Holding Inc
NASDAQ:MORF
Average P/E: 43.7
Negative Multiple: -15.9
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -0.4 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 409.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
163.1
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.3
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
10%
1.7
AU
CSL Ltd
ASX:CSL
19
11%
1.7
NL
argenx SE
XBRU:ARGX
32.8
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Morphic Holding Inc
NASDAQ:MORF
Average EV/EBITDA: 19.3
Negative Multiple: -10.5
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
0.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 217.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.9
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
56.4
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Morphic Holding Inc
NASDAQ:MORF
Average EV/EBIT: 21.1
Negative Multiple: -10.5
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
0.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 966.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
13%
1.4
AU
CSL Ltd
ASX:CSL
16
11%
1.5
NL
argenx SE
XBRU:ARGX
58
N/A N/A